Key Insights

Highlights

Treatment Research

1 treatments under study, led by Escitalopram

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00754793Phase 4Terminated

Sinusitis and Facial Pain Disorders Anti-Depression Trial

Showing all 1 trials

Research Network

Common Treatments

  • Escitalopram1

Active Sponsors

  • National Institutes of Health (NIH)1
  • Forest Laboratories1
  • University of Washington1

Top Investigators

Related Conditions

  • Depression1
  • Chronic Sinusitis1

Activity Timeline